Arvinas (ARVN) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Arvinas (NASDAQ: ARVN):

• 11/9/2026 – Arvinas was downgraded by Zacks Research from “strong-buy” to “hold”.
• 11/4/2026 – Arvinas was downgraded by Weiss Ratings from “sell (d)” to “sell (e+)”.
• 11/3/2026 – Arvinas is now covered by HC Wainwright. They set a “buy” rating and a $13.00 price target on the stock.
• 10/23/2026 – Arvinas was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 10/9/2026 – Arvinas was upgraded by Zacks Research from “hold” to “strong-buy”.
• 10/8/2026 – Arvinas was upgraded by Weiss Ratings from “sell (d)” to “sell (d+)”.

Arvinas Stock Performance

NASDAQ:ARVN opened at $6.87 on Friday. The stock’s 50-day simple moving average is $7.67 and its 200 day simple moving average is $9.45. Arvinas, Inc. has a 52-week low of $6.33 and a 52-week high of $14.51. The company has a market cap of $449.92 million, a P/E ratio of -28.62 and a beta of 1.81.

Arvinas (NASDAQ:ARVN) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.10. The firm had revenue of $0.50 million during the quarter, compared to the consensus estimate of $12.39 million. Arvinas had a negative return on equity of 2.00% and a negative net margin of 3.45%. The business’s revenue was down 98.8% compared to the same quarter last year. During the same period last year, the company earned ($0.48) earnings per share. As a group, equities analysts predict that Arvinas, Inc. will post 0.27 earnings per share for the current fiscal year.

Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut, that develops medicines using targeted protein degradation. Founded in 2013, the company applies its PROTAC technology to direct disease-related proteins for removal by the body’s natural protein-disposal system. Its research focuses primarily on cancer, including investigational therapies designed to target estrogen and androgen receptors. The company’s programs include vepdegestrant, an estrogen receptor degrader being developed with Pfizer for certain forms of breast cancer, as well as androgen receptor degraders being studied for prostate cancer.